Paul-Ehrlich-Institut

COVID-19 Vac­cine As­traZeneca

Commenting on the decision by Danish health authorities to pause vaccination of AstraZeneca's COVID-19 vaccine, the Paul-Ehrlich-Institut states:

So far, there is no evidence that the death in Denmark is causally linked to Corona vaccination with AstraZeneca’s COVID-19 vaccine. Following an initial review, the European Medicines Agency (EMA) maintains its positive evaluation of the authorised AstraZeneca vaccine.

As of 10 March 2021, 30 cases of thromboembolic events have been reported in more than 5 million people vaccinated with the AstraZeneca vaccine in the European Economic Area (EEA), according to the EMA. This number is no higher than the number of thromboembolic events that would occur statistically by chance in the exposed population even without vaccination.

In Germany, a total of 11 reports of different thromboembolic events have been reported in approximately 1.2 million vaccinations as of 11 March 2021. Four individuals died. In reviewing the currently available information on German and international reports of thromboembolic events following vaccination with AstraZeneca COVID-19 vaccine, there is currently no evidence that vaccination caused these illnesses. In agreement with the EMA, the Paul-Ehrlich-Institut believes that the benefits of vaccination outweigh the known risks.

The events that have occurred are being further investigated in close cooperation between the EMA and the national competent authorities (NCAs).

Updated: 11.03.2021